As of 2025-07-10, the EV/EBITDA ratio of Phathom Pharmaceuticals Inc (PHAT) is -3.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PHAT's latest enterprise value is 1,006.12 mil USD. PHAT's TTM EBITDA according to its financial statements is -285.61 mil USD. Dividing these 2 quantities gives us the above PHAT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 10.3x | 8.2x |
| Forward P/E multiples | 11.3x - 17.7x | 14.9x |
| Fair Price | (51.27) - (47.26) | (52.40) |
| Upside | -647.2% - -604.4% | -659.2% |
| Date | EV/EBITDA |
| 2025-07-07 | -3.35 |
| 2025-07-03 | -3.41 |
| 2025-07-02 | -3.41 |
| 2025-07-01 | -3.40 |
| 2025-06-30 | -3.58 |
| 2025-06-27 | -3.61 |
| 2025-06-26 | -3.57 |
| 2025-06-25 | -3.57 |
| 2025-06-24 | -3.62 |
| 2025-06-23 | -3.55 |
| 2025-06-20 | -3.78 |
| 2025-06-18 | -3.90 |
| 2025-06-17 | -3.80 |
| 2025-06-16 | -3.83 |
| 2025-06-13 | -3.83 |
| 2025-06-12 | -3.68 |
| 2025-06-11 | -3.44 |
| 2025-06-10 | -3.43 |
| 2025-06-09 | -3.39 |
| 2025-06-06 | -3.41 |
| 2025-06-05 | -2.38 |
| 2025-06-04 | -2.38 |
| 2025-06-03 | -2.44 |
| 2025-06-02 | -2.37 |
| 2025-05-30 | -2.27 |
| 2025-05-29 | -2.29 |
| 2025-05-28 | -2.23 |
| 2025-05-27 | -2.24 |
| 2025-05-23 | -2.22 |
| 2025-05-22 | -2.27 |
| 2025-05-21 | -2.19 |
| 2025-05-20 | -2.30 |
| 2025-05-19 | -2.31 |
| 2025-05-16 | -2.23 |
| 2025-05-15 | -2.08 |
| 2025-05-14 | -2.03 |
| 2025-05-13 | -2.04 |
| 2025-05-12 | -2.00 |
| 2025-05-09 | -2.00 |
| 2025-05-08 | -1.79 |
| 2025-05-07 | -1.82 |
| 2025-05-06 | -1.82 |
| 2025-05-05 | -1.86 |
| 2025-05-02 | -1.91 |
| 2025-05-01 | -2.05 |
| 2025-04-30 | -2.28 |
| 2025-04-29 | -2.30 |
| 2025-04-28 | -2.25 |
| 2025-04-25 | -2.24 |
| 2025-04-24 | -2.24 |